Moxifloxacin-AFT Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Moxifloxacin HCl

Indications/Uses

Community-acquired pneumonia caused by Strep pneumoniae, H. influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae or Moraxella catarrhalis. Complicated skin & skin structure infections caused by methicillin-susceptible Staph aureus, E. coli, Klebsiella pneumoniae or Enterobacter cloacae.

Dosage/Direction for Use

IV Adult 400 mg once daily infused over 60 min. Community-acquired pneumonia (IV to PO sequential therapy) Duration of treatment: 7-14 days. Complicated skin & skin structure infections (IV to PO sequential therapy) Duration of treatment: 7-21 days.

Contraindications

Hypersensitivity to moxifloxacin or other quinolones. History of tendon disease/disorder related to quinolone treatment. Congenital or documented acquired QT prolongation; electrolyte disturbances particularly in uncorrected hypokalaemia; clinically relevant bradycardia & heart failure w/ reduced left-ventricular ejection fraction; previous history of symptomatic arrhythmias. Concurrent use w/ other QT interval-prolonging drugs. Hepatic impairment (Child-Pugh C) & patients w/ increased transaminases >5 fold ULN. Pregnancy & lactation. Patients <18 yr.

MIMS Class

Quinolones

ATC Classification

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Regulatory Classification

POM

Presentation/Packing

Form

Moxifloxacin-AFT soln for infusion 400 mg/250 mL

Packing/Price

1's

Moxifloxacin-AFT

moxifloxacin

Manufacturer:

Joint Stock Company Halychpharm